Rani Therapeutics Holdings Stock Price Prediction
| RANI Stock | USD 1.99 0.04 2.05% |
Oversold Vs Overbought
46
Oversold | Overbought |
EPS Estimate Next Quarter (0.28) | EPS Estimate Current Year (1.01) | EPS Estimate Next Year (0.78) | Wall Street Target Price 11.5 | EPS Estimate Current Quarter (0.29) |
Using Rani Therapeutics hype-based prediction, you can estimate the value of Rani Therapeutics Holdings from the perspective of Rani Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Rani Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Rani because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Rani Therapeutics after-hype prediction price | USD 1.95 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Rani |
Rani Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Rani Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Rani Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Rani Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Rani Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Rani Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Rani Therapeutics' historical news coverage. Rani Therapeutics' after-hype downside and upside margins for the prediction period are 0.10 and 11.82, respectively. We have considered Rani Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Rani Therapeutics is risky at this time. Analysis and calculation of next after-hype price of Rani Therapeutics is based on 3 months time horizon.
Rani Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Rani Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rani Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Rani Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.32 | 9.79 | 0.04 | 0.00 | 5 Events / Month | 6 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.99 | 1.95 | 2.01 |
|
Rani Therapeutics Hype Timeline
Rani Therapeutics is at this time traded for 1.99. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of 0.0. Rani is estimated to decline in value after the next headline, with the price expected to drop to 1.95. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.01%, whereas the daily expected return is at this time at -0.32%. The volatility of related hype on Rani Therapeutics is about 111885.71%, with the expected price after the next announcement by competition of 1.99. About 31.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.68. Rani Therapeutics recorded a loss per share of 1.05. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in about 5 days. Check out Rani Therapeutics Basic Forecasting Models to cross-verify your projections.Rani Therapeutics Related Hype Analysis
Having access to credible news sources related to Rani Therapeutics' direct competition is more important than ever and may enhance your ability to predict Rani Therapeutics' future price movements. Getting to know how Rani Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Rani Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IKNA | Ikena Oncology | (0.05) | 4 per month | 0.00 | (0.13) | 1.80 | (1.74) | 5.87 | |
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.19) | 6.21 | (9.35) | 34.87 | |
| HCWB | HCW Biologics | 0.33 | 4 per month | 8.25 | 0.08 | 22.00 | (16.67) | 352.85 | |
| TPST | Tempest Therapeutics | (0.47) | 4 per month | 0.00 | (0.12) | 6.38 | (8.53) | 29.55 | |
| SCPH | Scpharmaceuticals | (0.03) | 8 per month | 0.00 | (0.15) | 4.30 | (7.09) | 20.70 | |
| MIST | Milestone Pharmaceuticals | 0.01 | 6 per month | 1.57 | 0.1 | 7.19 | (2.11) | 18.66 | |
| MCRB | Seres Therapeutics | (0.06) | 9 per month | 5.57 | 0.04 | 10.84 | (9.78) | 28.84 | |
| LUMO | Lumos Pharma | (0.05) | 6 per month | 2.95 | 0.02 | 5.95 | (5.19) | 16.25 |
Rani Therapeutics Additional Predictive Modules
Most predictive techniques to examine Rani price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Rani using various technical indicators. When you analyze Rani charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Rani Therapeutics Predictive Indicators
The successful prediction of Rani Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Rani Therapeutics Holdings, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Rani Therapeutics based on analysis of Rani Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Rani Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Rani Therapeutics's related companies. | 2023 | 2024 (projected) | Graham Number | 3.89 | 3.69 | Receivables Turnover | 0.31 | 0.29 |
Story Coverage note for Rani Therapeutics
The number of cover stories for Rani Therapeutics depends on current market conditions and Rani Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Rani Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Rani Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Rani Therapeutics Short Properties
Rani Therapeutics' future price predictability will typically decrease when Rani Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Rani Therapeutics Holdings often depends not only on the future outlook of the potential Rani Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rani Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 25.5 M | |
| Cash And Short Term Investments | 48.5 M |
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |